Alternative splicing of RAGE: roles in biology and disease

Front Biosci (Landmark Ed). 2011 Jun 1;16:2756-70. doi: 10.2741/3884.

Abstract

The Receptor for Advanced Glycation End-products (RAGE) is a complex, multi-ligand signaling system implicated in the pathogenesis of diabetes, cardiovascular disease and various cancers. RAGE undergoes extensive alternative splicing to produce a variety of transcripts with diverse functions, including soluble antagonists and variants with altered ligand binding domains. Studies focused on the major soluble variant (RAGEv1/esRAGE) have revealed this to function by binding RAGE-ligands and preventing activation of RAGE signaling in vascular and tumor cells. Furthermore, measurement of this variant in human serum has revealed that RAGEv1/esRAGE levels may represent a novel biomarker for RAGE-ligand related pathogenic states. Understanding the full plethora of RAGE alternative splicing and its regulation is central to elucidating the role of RAGE in biology and disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alternative Splicing*
  • Animals
  • Humans
  • Ligands
  • Models, Biological
  • Promoter Regions, Genetic
  • Protein Structure, Tertiary
  • RNA, Messenger / genetics
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / chemistry
  • Receptors, Immunologic / genetics*
  • Receptors, Immunologic / metabolism
  • Signal Transduction

Substances

  • Ligands
  • RNA, Messenger
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic